Structure-guided deimmunization of therapeutic proteins.

Area of Science:

• Biotechnology
• Computational Biology
• Protein Engineering

Background:

• Therapeutic proteins offer revolutionary treatments but face challenges with immunogenicity.
• Mitigating anti-therapeutic immune responses early in development is crucial.
• Deimmunizing mutations must balance reduced immunogenicity with protein structure and function.

Purpose of the Study:

• To develop a novel approach, EpiSweep, for simultaneously optimizing protein structure and reducing immunogenicity.
• To identify Pareto optimal trade-offs between protein stability and immune response.
• To guide protein engineers toward promising immunotolerant biotherapeutic candidates.

Main Methods:

• EpiSweep algorithm integrates structure-based protein design and sequence-based deimmunization.
• Utilizes a molecular mechanics energy function for structure and a T-cell epitope predictor for immunogenicity.
• Employs integer programming techniques to efficiently find Pareto frontiers in the design space.

Main Results:

• EpiSweep designs for erythropoietin and staphylokinase show predicted improvements over previous experimental methods.
• Demonstrates capacity for deimmunizing entire proteins, analyzing numerous epitopes and side-chain interactions.
• Identifies sets of mutations achieving Pareto optimal balance between structure and immunogenicity.

Conclusions:

• EpiSweep is a powerful protein design tool for biotherapeutic development.
• Enables simultaneous optimization of protein structure and immunogenicity.
• Facilitates the creation of more effective and safer immunotolerant biotherapeutics.